Logo     Print Page  Close Window

Investor FAQs

 Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma.

 Fibrocell is located at 405 Eagleview Boulevard, Exton, PA 19341, USA. The main office telephone number is (484) 713-6000 and fax number is (484) 713-6001.

 Fibrocell is incorporated in the state of Delaware.

 December 31

 The company’s stock is traded on the NASDAQ Global Market. The ticker symbol is FCSC.

 Send communications about transfer requirements, lost certificates and changes of address to:
Broadridge Corporate Issuer Solutions
P.O. Box 1342
Brentwood, NY 11717

Overnight Mail Address:
Broadridge Corporate Issuer Solutions
1155 Long Island Avenue
Edgewood, NY 11717
Phone #: 1-877-830-4936
Website: https://investor.broadridge.com/

 Shares cannot be purchased directly through the company.

 This information appears in the annual proxy statement posted on our SEC Filings page and may also be found with prior proxy filings at www.sec.gov.

  PricewaterhouseCoopers LLP
Two Commerce Square
Suite 1700
2001 Market Street
Philadelphia, PA 19103


The company’s news releases are archived on our Press Releases pages.

 You can view the SEC filings for Fibrocell on our SEC Filings page or at www.sec.gov.

 Visit our Careers page to learn more about career opportunities

 Click here to submit your inquiries.